Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Lin

Interventional Cardiology Phoenix, AZ Medical Doctor

NPI 1982601043 CMS profile 361970

3805 E Bell Rd, Suite 3100, Phoenix, AZ 85032

Open in the dashboard

General payments

$3,537

114 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Lin of Phoenix, AZ is reported in the CMS Open Payments database as having received $3,537 across 114 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 30th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $505 17
2024 General $863 28
2023 General $667 16
2022 General $668 29
2021 General $322 12
2020 General $227 7
2019 General $285 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Lin
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to David Lin were reported at $505. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year David Lin Interventional Cardiology median Middle half National median
2019 $285 $1,097 $329–$3,048 $163
2020 $227 $473 $161–$1,480 $114
2021 $322 $677 $233–$1,827 $132
2022 $668 $978 $333–$2,724 $149
2023 $667 $1,136 $382–$2,986 $160
2024 $863 $1,181 $395–$3,326 $164
2025 $505 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $854 19 payments
  2. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $414 15 payments
  3. Medtronic, Inc. $254 2 payments
  4. Pfizer Inc. $232 14 payments
  5. Chiesi USA, Inc. $175 1 payment
  6. Novo Nordisk Inc $174 8 payments
  7. Edwards Lifesciences Corporation $164 1 payment
  8. Amgen Inc. $131 8 payments
  9. Novartis Pharmaceuticals Corporation $119 6 payments
  10. Kestra Medical Technology Services, Inc. $113 4 payments
  11. Other $907 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,372 111 payments
  2. Education $165 3 payments
Products named General payments · program years 2019–2025
  1. LifeVest $414 15 payments
  2. ELIQUIS $232 14 payments
  3. KENGREAL $175 1 payment
  4. Wegovy $174 8 payments
  5. Micra $173 1 payment
  6. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $164 1 payment
  7. MITRACLIP $159 2 payments
  8. CardioMEMS HF System $157 6 payments
  9. JETI $149 1 payment
  10. CARDIOMEMS $144 5 payments
  11. Other $1,660 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 64 drugs

Part D claims

7,184

Median for Interventional Cardiology: 2,236

Drug cost

$1,218,137

Median for Interventional Cardiology: $380,412

Branded share of claims

26.2%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 571 $665,985
Xarelto Rivaroxaban Brand 127 $162,848
Repatha Sureclick Evolocumab Brand 166 $148,527
Entresto Sacubitril/Valsartan Brand 68 $83,611
Brilinta Ticagrelor Brand 56 $59,817
Praluent Pen Alirocumab Brand 13 $14,494
Metoprolol Succinate Generic 465 $6,462
Atorvastatin Calcium Generic 660 $6,460
Rosuvastatin Calcium Generic 280 $4,248
Ranolazine Er Ranolazine Brand 32 $3,882

The 10 drugs with the highest cost, of 64 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$148,096

Medicare's payments for the services billed

Medicare patients

833

Average age 76

Services billed

2,517

399 women, 434 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Arthritis 53%
Chronic kidney disease 38%
Atrial fibrillation 36%
Diabetes 35%
Heart failure 32%
COPD 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $66
$66 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $60
$60 — —
ELIQUIS
  • PFIZER INC. $22
  • E.R. Squibb & Sons, L.L.C. $20
$41 571 —
Repatha
  • Amgen Inc. $18
$18 166 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $17
$17 68 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

114 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record